Chemical formula: C₁₇H₁₄Cl₂F₂N₂O₃ Molecular mass: 403.207 g/mol PubChem compound: 449193
Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D05AX06 | D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use | |
| R03DX07 | Roflumilast | R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| DALIRESP Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| DAXAS Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Roflumilast is an active ingredient of these brands:
United States (US)Brazil (BR)Canada (CA)Croatia (HR)Finland (FI)Hong Kong (HK)Ireland (IE)Netherlands (NL)Poland (PL)Romania (RO)South Africa (ZA)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
